A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer

BCG and Alternative Therapies to BCG Therapy for Non-Muscle-Invasive Bladder Cancer

Bladder cancer is a heterogeneous disease. Treatment decisions are mostly decided based on disease stage (non-muscle invasive or muscle invasive). Patients with muscle-invasive disease will be offered a radical treatment combined with systemic therapy, while in those with non-muscle-invasive disease, an attempt to resect the tumor endoscopically will usually be followed by different intravesical instillations. The goal of intravesical therapy is to decrease the recurrence and/or progression of the tumor. In the current landscape of bladder cancer treatment, BCG is given intravesically to induce an inflammatory response and recruit immune cells to attack the malignant cells and induce immune memory. While the response to BCG treatment has changed the course of bladder cancer management and spared many "bladders", some patients may develop BCG-unresponsive disease, leaving radical surgery as the best choice of curative treatment. As a result, a lot of effort has been put into identifying novel therapies like systemic pembrolizumab and Nadofaragene-Firadenovac to continue sparing bladders if BCG is ineffective. Moreover, recent logistic issues with BCG production caused a worldwide BCG shortage, re-sparking interest in alternative BCG treatments including mitomycin C, sequential gemcitabine with docetaxel, and others. This review encompasses both the historic and current role of BCG in the treatment of non-muscle-invasive bladder cancer, revisiting BCG alternative therapies and reviewing the novel therapeutics that were approved for the BCG-unresponsive stage or are under active investigation.

Perturbation of Copper Homeostasis Sensitizes Cancer Cells to Elevated Temperature

Temporary elevation of tumor temperature, also known as hyperthermia, is a safe and well-tolerated treatment modality. The efficacy of hyperthermia can be improved by efficient thermosensitizers, and various candidate drugs, including inhibitors of the heat stress response, have been explored in vitro and in animal models, but clinically relevant thermosensitizers are lacking. Here, we employ unbiased in silico approaches to uncover new mechanisms and compounds that could be leveraged to increase the thermosensitivity of cancer cells. We then focus on elesclomol, a well-performing compound, which amplifies cell killing by hyperthermia by 5- to 20-fold in cell lines and outperforms clinically applied chemotherapy when combined with hyperthermia in vitro. Surprisingly, our findings suggest that the thermosensitizing effects of elesclomol are independent of its previously reported modes of action but depend on copper shuttling. Importantly, we show that, like elesclomol, multiple other copper shuttlers can thermosensitize, suggesting that disturbing copper homeostasis could be a general strategy for improving the efficacy of hyperthermia.

Structure and magnetic properties of SiO2-FeO-CaO-Na2O bioactive glass-ceramic system for magnetic fluid hyperthermia application

Ferrimagnetic glass-ceramics comprising maghemite crystals were synthesized for magnetic fluid hyperthermia (MFH) usage. The present work is focused on the result of the chemical composition and heat treatment temperature on the magnetic behavior of ( 60 - x ) S i O 2 - ( 10 + x ) F e O - 20 C a O - 10 N a 2 O , 0 ≤ x ≤ 30 glass-ceramic system. It was observed that with the increasing of FeO from 10 to 40 wt% in the glass-ceramic compound, the percentage of maghemite phase increased. It was also seen that in the low heat treatment temperature (680 °C ), by adding iron oxide up to 30 wt%, iron cations acts as a network former, and more than this amount acts as a network modifier. In contrast, iron cations in the same composition range at high temperatures (840 °C ), acts as a network modifier. According to the VSM results, the maximum magnetization of glass-ceramics incremented from 0.23 emu/g to 0.30 emu/g with the increase in FeO percentage. It was also observed that with the increment of iron oxide percentage, the morphology of maghemite crystals changed from spherical to dumbbell-shaped.

Cold Nanozyme for Precise Enzymatic Antitumor Immunity

Precise catalysis is pursued for the biomedical applications of artificial enzymes. It is feasible to precisely control the catalysis of artificial enzymes via tunning the temperature-dependent enzymatic kinetics. The safety window of cold temperatures (4-37 °C) for the human body is much wider than that of thermal temperatures (37-42 °C). Although the development of cold-activated artificial enzymes is promising, there is currently a lack of suitable candidates. Herein, a cold-activated artificial enzyme is presented with Bi₂Fe₄O₉ nanosheets (NSs) as a paradigm. The as-obtained Bi₂Fe₄O₉ NSs possess glutathione oxidase (GSHOx)-like activity under cold temperature due to their pyroelectricity. Bi₂Fe₄O₉ NSs trigger the cold-enzymatic death of tumor cells via apoptosis and ferroptosis, and minimize the off-target toxicity to normal tissues. Moreover, an interventional device is fabricated to intelligently and remotely control the enzymatic activity of Bi₂Fe₄O₉ NSs on a smartphone. With Bi₂Fe₄O₉ NSs as an in situ vaccine, systemic antitumor immunity is successfully activated to suppress tumor metastasis and relapse. Moreover, blood biochemistry analysis and histological examination indicate the high biosafety of Bi₂Fe₄O₉ NSs for in vivo applications. This cold nanozyme provides a strategy for cancer vaccines, which can benefit the precise control over catalytic nanomedicines.